![Michael Panzara](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: - $ al 30/06/2026
Michael A. Panzara is currently Director at Cadenza Bio, Inc., Independent Director at LeonaBio, Inc. since 2022, and Chief Medical Officer at Immunic, Inc. starting in 2026.
Formerly, Dr. Panzara was Director at Wave Life Sciences UK Ltd. from 2018 to 2022, Chief Medical Officer & Head-Therapeutics at Wave Life Sciences Ltd. from 2020 to 2022, Chief Medical Officer at Neurvati Neurosciences, Inc. from 2022 to 2026, Head-Multiple Sclerosis & Neurology at Genzyme Corp.
from 2009 to 2016, and Chief Medical Officer-Neurology & Vice President at Biogen, Inc. from 2001 to 2009.
Education includes an undergraduate degree from the University of Pennsylvania in 1989, a doctorate from Stanford University School of Medicine in 1994, and a graduate degree from Harvard T.H.
Chan School of Public Health in 2002.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LEONABIO, INC. -.--% | 23/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| LEONABIO, INC. | Director/Miembro de la Junta | 18/03/2022 |
| IMMUNIC, INC. | Director Técnico/Científico/I+D | 24/04/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
Neurvati Neurosciences, Inc.
 Neurvati Neurosciences, Inc. BiotechnologyHealth Technology Develops therapies for neurological and psychiatric disorders | Director Técnico/Científico/I+D | 01/03/2026 |
| WAVE LIFE SCIENCES LTD. | Director Técnico/Científico/I+D | 14/10/2022 |
Wave Life Sciences UK Ltd.
 Wave Life Sciences UK Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Director/Miembro de la Junta | 01/01/2022 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01/07/2016 |
| BIOGEN INC. | Corporate Officer/Principal | 01/09/2009 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
LeonaBio, Inc.
 LeonaBio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Wave Life Sciences Ltd.
 Wave Life Sciences Ltd. BiotechnologyHealth Technology Operates as a biotechnology company that develops RNA oligonucleotides medicines | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard T.H. Chan School of Public Health
 Harvard T.H. Chan School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wave Life Sciences UK Ltd.
Wave Life Sciences UK Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Immunic, Inc.
 Immunic, Inc. Pharmaceuticals: MajorHealth Technology Develops oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases | Health Technology |
Neurvati Neurosciences, Inc.
Neurvati Neurosciences, Inc. BiotechnologyHealth Technology Develops therapies for neurological and psychiatric disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
